

# Stuart J Pocock

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8240246/publications.pdf>

Version: 2024-02-01

404  
papers

130,144  
citations

1238

110  
h-index

105

348  
g-index

414  
all docs

414  
docs citations

414  
times ranked

108802  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Lancet, The</i> , 2007, 370, 1453-1457.                     | 13.7 | 9,433     |
| 2  | The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Journal of Clinical Epidemiology</i> , 2008, 61, 344-349.   | 5.0  | 7,988     |
| 3  | The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. <i>PLoS Medicine</i> , 2007, 4, e296.                          | 8.4  | 7,961     |
| 4  | Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. <i>New England Journal of Medicine</i> , 2010, 363, 1597-1607.  | 27.0 | 6,189     |
| 5  | The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. <i>International Journal of Surgery</i> , 2014, 12, 1495-1499. | 2.7  | 5,967     |
| 6  | Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients. <i>New England Journal of Medicine</i> , 2011, 364, 2187-2198.  | 27.0 | 5,447     |
| 7  | The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. <i>Annals of Internal Medicine</i> , 2007, 147, 573.           | 3.9  | 5,228     |
| 8  | Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 311-322.  | 27.0 | 5,070     |
| 9  | Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>BMJ: British Medical Journal</i> , 2007, 335, 806-808.          | 2.3  | 4,798     |
| 10 | Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. <i>PLoS Medicine</i> , 2007, 4, e297.   | 8.4  | 3,710     |
| 11 | Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. <i>New England Journal of Medicine</i> , 2019, 380, 1695-1705.   | 27.0 | 3,312     |
| 12 | Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.   | 27.0 | 2,821     |
| 13 | Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. <i>New England Journal of Medicine</i> , 2011, 364, 11-21.  | 27.0 | 2,491     |
| 14 | Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. <i>Lancet, The</i> , 2003, 362, 759-766.   | 13.7 | 1,752     |
| 15 | Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). <i>Epidemiology</i> , 2007, 18, 805-835.   | 2.7  | 1,717     |
| 16 | Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. <i>International Journal of Surgery</i> , 2014, 12, 1500-1524.                                  | 2.7  | 1,698     |
| 17 | Bivalirudin during Primary PCI in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2008, 358, 2218-2230.   | 27.0 | 1,693     |
| 18 | Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. <i>New England Journal of Medicine</i> , 2009, 361, 2436-2448.  | 27.0 | 1,633     |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2016, 374, 2235-2245.   | 27.0 | 1,423     |
| 20 | Bivalirudin for Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2006, 355, 2203-2216.  | 27.0 | 1,367     |
| 21 | Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. <i>Annals of Internal Medicine</i> , 2007, 147, W.  | 3.9  | 1,339     |
| 22 | 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. <i>European Heart Journal</i> , 2014, 35, 2383-2431.  | 2.2  | 1,253     |
| 23 | Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. <i>Lancet, The</i> , 2009, 373, 2125-2135.         | 13.7 | 1,243     |
| 24 | The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement. <i>Epidemiology</i> , 2007, 18, 800-804.   | 2.7  | 1,237     |
| 25 | Reporting of Noninferiority and Equivalence Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2594.   | 7.4  | 1,227     |
| 26 | The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies*. <i>Bulletin of the World Health Organization</i> , 2007, 85, 867-872. | 3.3  | 1,159     |
| 27 | Subgroup analysis and other (mis)uses of baseline data in clinical trials. <i>Lancet, The</i> , 2000, 355, 1064-1069.   | 13.7 | 1,028     |
| 28 | Reporting of Noninferiority and Equivalence Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1152.   | 7.4  | 1,027     |
| 29 | Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. <i>European Heart Journal</i> , 2013, 34, 1404-1413.   | 2.2  | 921       |
| 30 | Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. <i>Statistics in Medicine</i> , 2002, 21, 2917-2930.                                   | 1.6  | 888       |
| 31 | The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. <i>Preventive Medicine</i> , 2007, 45, 247-251.                        | 3.4  | 887       |
| 32 | Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2016, 375, 2223-2235.   | 27.0 | 843       |
| 33 | Predictors of mortality and morbidity in patients with chronic heart failure. <i>European Heart Journal</i> , 2006, 27, 65-75.  | 2.2  | 822       |
| 34 | SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. <i>Lancet, The</i> , 2020, 396, 819-829.                                 | 13.7 | 816       |
| 35 | Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 40-47.  | 2.8  | 809       |
| 36 | Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019, 381, 2032-2042.  | 27.0 | 683       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Statistical Problems in the Reporting of Clinical Trials. <i>New England Journal of Medicine</i> , 1987, 317, 426-432.   | 27.0 | 668       |
| 38 | Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2009, 360, 1946-1959.  | 27.0 | 657       |
| 39 | Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. <i>Lancet</i> , The, 2009, 373, 1190-1197.               | 13.7 | 649       |
| 40 | Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. <i>Lancet</i> , The, 2017, 390, 2160-2170. | 13.7 | 597       |
| 41 | Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet</i> , The, 2018, 391, 2346-2355.              | 13.7 | 597       |
| 42 | A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2556-2566.  | 2.8  | 590       |
| 43 | Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design. <i>Statistics in Medicine</i> , 1992, 11, 1685-1704.   | 1.6  | 563       |
| 44 | Randomized Trials or Observational Tribulations?. <i>New England Journal of Medicine</i> , 2000, 342, 1907-1909.   | 27.0 | 550       |
| 45 | Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. <i>Lancet</i> , The, 2013, 382, 1714-1722.                                    | 13.7 | 537       |
| 46 | Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. <i>Circulation</i> , 2007, 116, 1482-1487.   | 1.6  | 528       |
| 47 | Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. <i>New England Journal of Medicine</i> , 2019, 381, 1820-1830.  | 27.0 | 523       |
| 48 | Long-Term Outcome of a Routine Versus Selective Invasive Strategy in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2435-2445.                                 | 2.8  | 515       |
| 49 | Comparison of Propensity Score Methods and Covariate Adjustment. <i>Journal of the American College of Cardiology</i> , 2017, 69, 345-357.   | 2.8  | 468       |
| 50 | Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. <i>Lancet</i> , The, 2015, 385, 1729-1737.   | 13.7 | 461       |
| 51 | Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2224-2234.   | 2.8  | 445       |
| 52 | Bivalirudin Started during Emergency Transport for Primary PCI. <i>New England Journal of Medicine</i> , 2013, 369, 2207-2217.   | 27.0 | 443       |
| 53 | Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 240-261.  | 1.6  | 428       |
| 54 | Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet</i> , The, 2020, 396, 1895-1904.  | 13.7 | 425       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. <i>Lancet</i> , The, 2011, 377, 2193-2204. | 13.7 | 421       |
| 56 | Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. <i>Lancet</i> , The, 2002, 359, 1686-1689.  | 13.7 | 410       |
| 57 | The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. <i>European Heart Journal</i> , 2012, 33, 176-182.   | 2.2  | 386       |
| 58 | Prevalence, Impact, and Predictive Value of Detecting Subclinical Coronary and Carotid Atherosclerosis in Asymptomatic Adults. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1065-1074.   | 2.8  | 379       |
| 59 | Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort. <i>Circulation</i> , 2015, 131, 2104-2113.  | 1.6  | 352       |
| 60 | Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 1444-1451.  | 13.7 | 351       |
| 61 | BMI and risk of dementia in two million people over two decades: a retrospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , the, 2015, 3, 431-436.   | 11.4 | 343       |
| 62 | Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019, 40, 2632-2653.   | 2.2  | 335       |
| 63 | Impact of Bleeding on Mortality After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 654-664.  | 2.9  | 329       |
| 64 | Body Mass Index and Prognosis in Patients With Chronic Heart Failure. <i>Circulation</i> , 2007, 116, 627-636.   | 1.6  | 328       |
| 65 | Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>European Journal of Heart Failure</i> , 2009, 11, 170-177.                                       | 7.1  | 326       |
| 66 | Effect of Early Metoprolol on Infarct Size in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2013, 128, 1495-1503.  | 1.6  | 321       |
| 67 | Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron deficient heart failure patients: an individual patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 125-133.   | 7.1  | 317       |
| 68 | Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. <i>European Heart Journal</i> , 2009, 30, 1457-1466.                                  | 2.2  | 315       |
| 69 | Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1298-1310.   | 2.8  | 314       |
| 70 | Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. <i>Lancet</i> , The, 2018, 391, 2107-2115.  | 13.7 | 309       |
| 71 | A Polypill Strategy to Improve Adherence. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2071-2082.  | 2.8  | 290       |
| 72 | Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 591.   | 7.4  | 266       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 73 | Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 427-437.   | 4.4  | 247       |
| 74 | Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2979-2991.  | 2.8  | 240       |
| 75 | Adaptive increase in sample size when interim results are promising: A practical guide with examples. <i>Statistics in Medicine</i> , 2011, 30, 3267-3284.   | 1.6  | 237       |
| 76 | Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure. <i>Circulation</i> , 2007, 115, 3111-3120.   | 1.6  | 235       |
| 77 | Issues in the reporting of epidemiological studies: a survey of recent practice. <i>BMJ: British Medical Journal</i> , 2004, 329, 883.   | 2.3  | 231       |
| 78 | Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure. <i>Circulation</i> , 2006, 113, 986-994.  | 1.6  | 229       |
| 79 | Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. <i>European Heart Journal</i> , 2007, 28, 1936-1945.                  | 2.2  | 223       |
| 80 | Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 326-336.   | 1.6  | 222       |
| 81 | Antithrombotic Strategies in Patients With Acute Coronary Syndromes Undergoing Early Invasive Management. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2497.   | 7.4  | 217       |
| 82 | Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. <i>Circulation</i> , 2021, 143, 337-349.  | 1.6  | 217       |
| 83 | A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2001, 323, 75-81. | 2.3  | 216       |
| 84 | Effects of Icosapent Ethyl on Total Ischemic Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2791-2802.   | 2.8  | 208       |
| 85 | The Primary Outcome Fails – What Next?. <i>New England Journal of Medicine</i> , 2016, 375, 861-870.   | 27.0 | 204       |
| 86 | Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , 2021, 144, 1284-1294.                                      | 1.6  | 195       |
| 87 | Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. <i>European Journal of Heart Failure</i> , 2014, 16, 33-40.                                       | 7.1  | 186       |
| 88 | Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013, 15, 1082-1094.                                 | 7.1  | 182       |
| 89 | Interim Analyses in Randomized Clinical Trials: Ramifications and Guidelines for Practitioners. <i>Biometrics</i> , 1987, 43, 213.   | 1.4  | 178       |
| 90 | Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design. <i>Statistics in Medicine</i> , 1994, 13, 197-198.   | 1.6  | 176       |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 91  | Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. <i>Circulation</i> , 2021, 143, 310-321.  | 1.6  | 168       |
| 92  | Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2008, 29, 2641-2650.   | 2.2  | 164       |
| 93  | Long-Term Benefit of Early Pre-Reperfusion Metoprolol Administration in Patients With Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2356-2362.  | 2.8  | 162       |
| 94  | Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 75, 590-604.  | 2.8  | 160       |
| 95  | Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278. | 7.1  | 155       |
| 96  | Angiographic Surrogate End Points in Drug-Eluting Stent Trials. <i>Journal of the American College of Cardiology</i> , 2008, 51, 23-32.   | 2.8  | 153       |
| 97  | Predicting 30-Day Mortality for Patients With Acute Heart Failure in the Emergency Department. <i>Annals of Internal Medicine</i> , 2017, 167, 698.   | 3.9  | 152       |
| 98  | Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). <i>Cardiovascular Diabetology</i> , 2018, 17, 150.   | 6.8  | 149       |
| 99  | Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. <i>European Heart Journal</i> , 2022, 43, 416-424.  | 2.2  | 144       |
| 100 | When (Not) to Stop a Clinical Trial for Benefit. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2228.   | 7.4  | 139       |
| 101 | The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.  | 7.1  | 139       |
| 102 | Insulin glargine and malignancy: an unwarranted alarm. <i>Lancet, The</i> , 2009, 374, 511-513.   | 13.7 | 135       |
| 103 | The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. <i>American Heart Journal</i> , 2016, 171, 82-91.   | 2.7  | 132       |
| 104 | The agonising negative trend in monitoring of clinical trials. <i>Lancet, The</i> , 1999, 354, 1983-1988.   | 13.7 | 129       |
| 105 | Feasibility and Exploratory Efficacy Evaluation of the Embrella Embolic Deflector System for the Prevention of Cerebral Emboli in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1146-1155.   | 2.9  | 127       |
| 106 | Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. <i>Lancet, The</i> , 2018, 391, 850-859.   | 13.7 | 125       |
| 107 | Ticagrelor With or Without Aspirin After Complex PPCI. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2414-2424.  | 2.8  | 122       |
| 108 | Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. <i>Circulation</i> , 2021, 144, 1476-1484.  | 1.6  | 121       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 109 | Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications. <i>Circulation</i> , 2010, 121, 43-51.  | 1.6  | 120       |
| 110 | Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients. <i>BMJ: British Medical Journal</i> , 2005, 331, 869.                       | 2.3  | 115       |
| 111 | Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 1203-1212.                             | 2.2  | 114       |
| 112 | Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL) Tj ETQq0 0 0 rgeBT /Overlock 10 T  | 13.7 | 114       |
| 113 | The Primary Outcome Is Positive " Is That Good Enough?. <i>New England Journal of Medicine</i> , 2016, 375, 971-979.   | 27.0 | 112       |
| 114 | Long-Term Use of Cardiovascular Drugs. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1273-1285.   | 2.8  | 111       |
| 115 | 2-Year Outcomes of High-Bleeding-Risk Patients After Polymer-Free Drug-Coated Stents. <i>Journal of the American College of Cardiology</i> , 2017, 69, 162-171.  | 2.8  | 109       |
| 116 | Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , 2016, 182, 125-134.  | 2.7  | 108       |
| 117 | Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , 2022, 145, 184-193.  | 1.6  | 106       |
| 118 | Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1397-1407.  | 2.8  | 105       |
| 119 | Trials stopped early: too good to be true?. <i>Lancet, The</i> , 1999, 353, 943-944.   | 13.7 | 103       |
| 120 | The pros and cons of noninferiority trials. <i>Fundamental and Clinical Pharmacology</i> , 2003, 17, 483-490.  | 1.9  | 102       |
| 121 | Effect of Rosuvastatin on Repeat Heart Failure Hospitalizations. <i>JACC: Heart Failure</i> , 2014, 2, 289-297.  | 4.1  | 99        |
| 122 | Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 671-680. | 2.2  | 96        |
| 123 | Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1381-1392.  | 2.8  | 94        |
| 124 | Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020, 41, 3533-3545.     | 2.2  | 93        |
| 125 | Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2383-2392.   | 7.1  | 93        |
| 126 | Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , 2022, 43, e17-e25.  | 2.2  | 92        |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 127 | Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2020, 43, 1546-1552.   | 8.6  | 92        |
| 128 | Global geographical variations in ST-segment elevation myocardial infarction management and post-discharge mortality. <i>International Journal of Cardiology</i> , 2017, 245, 27-34.   | 1.7  | 91        |
| 129 | Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. <i>European Heart Journal</i> , 2020, 41, 3743-3749.  | 2.2  | 89        |
| 130 | Diagnostic and Prognostic Implications of Coronary Flow Capacity. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1670-1680.  | 2.9  | 87        |
| 131 | Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. <i>Lancet</i> , 2018, 392, 1127-1137. | 13.7 | 87        |
| 132 | Estimation issues in clinical trials and overviews. <i>Statistics in Medicine</i> , 1990, 9, 657-671.  | 1.6  | 84        |
| 133 | Categorisation of continuous risk factors in epidemiological publications: a survey of current practice. <i>Epidemiologic Perspectives and Innovations</i> , 2010, 7, 9.   | 7.0  | 84        |
| 134 | The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. <i>European Heart Journal</i> , 2013, 34, 2823-2829.                               | 2.2  | 79        |
| 135 | The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 300.   | 1.6  | 79        |
| 136 | Empagliflozin and Major Renal Outcomes in Heart Failure. <i>New England Journal of Medicine</i> , 2021, 385, 1531-1533.  | 27.0 | 78        |
| 137 | Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1186-1197.   | 7.1  | 75        |
| 138 | Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1609-1621.   | 2.8  | 75        |
| 139 | Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 1803-1813.  | 7.1  | 75        |
| 140 | Statistical and ethical issues in monitoring clinical trials. <i>Statistics in Medicine</i> , 1993, 12, 1459-1469.   | 1.6  | 74        |
| 141 | Statistical Controversies in Reporting of Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2648-2662.   | 2.8  | 72        |
| 142 | The win ratio approach for composite endpoints: practical guidance based on previous experience. <i>European Heart Journal</i> , 2020, 41, 4391-4399.  | 2.2  | 72        |
| 143 | Current controversies in data monitoring for clinical trials. <i>Clinical Trials</i> , 2006, 3, 513-521.   | 1.6  | 71        |
| 144 | Impact of major bleeding and blood transfusions after cardiac surgery: Analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. <i>American Heart Journal</i> , 2012, 163, 522-529.   | 2.7  | 71        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 145 | The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021, 42, 3011-3020.  | 2.2  | 71        |
| 146 | Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. <i>European Heart Journal</i> , 2019, 40, 743-751.  | 2.2  | 70        |
| 147 | Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-term follow up of antithrombotic management patterns in acute) Tj ETQq1 1 0.784314 rgBT /Overlock 10 69<br>509-517.   | 1.0  | 69        |
| 148 | A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. <i>Lancet</i> , The, 2021, 398, 1974-1983.   | 13.7 | 69        |
| 149 | Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials. <i>Circulation</i> , 2018, 138, 570-577.   | 1.6  | 66        |
| 150 | Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. <i>American Journal of Cardiology</i> , 2004, 94, 1023-1027.   | 1.6  | 65        |
| 151 | Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.   | 2.2  | 65        |
| 152 | Translating statistical findings into plain English. <i>Lancet</i> , The, 2009, 373, 1926-1928.   | 13.7 | 64        |
| 153 | Reduction in Cardiac Mortality With Bivalirudin in Patients With and Without Major Bleeding. <i>Journal of the American College of Cardiology</i> , 2014, 63, 15-20.  | 2.8  | 64        |
| 154 | Short Telomere Load, Telomere Length, and Subclinical Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2467-2476.  | 2.8  | 64        |
| 155 | Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2019, 151, 20-32.  | 2.8  | 63        |
| 156 | Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2909-2919.  | 2.8  | 63        |
| 157 | Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2015, 65, 27-38.   | 2.8  | 62        |
| 158 | The perils of surrogate endpoints. <i>European Heart Journal</i> , 2015, 36, 2212-2218.   | 2.2  | 61        |
| 159 | Intensive versus Guideline Blood Pressure and Lipid Lowering in Patients with Previous Stroke: Main Results from the Pilot "Prevention of Decline in Cognition after Stroke Trial"™ (PODCAST) Randomised Controlled Trial. <i>PLoS ONE</i> , 2017, 12, e0164608.  | 2.5  | 60        |
| 160 | Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1616-1628.   | 2.8  | 60        |
| 161 | Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2403-2413.  | 2.8  | 60        |
| 162 | Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. <i>American Heart Journal</i> , 2021, 231, 121-127. | 2.7  | 60        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. <i>European Journal of Heart Failure</i> , 2010, 12, 557-565.  | 7.1 | 59        |
| 164 | Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 754-765.   | 2.8 | 59        |
| 165 | Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1846-1857.   | 2.8 | 58        |
| 166 | Making Sense of Statistics in Clinical Trial Reports. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2536-2549.   | 2.8 | 57        |
| 167 | Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study. <i>European Heart Journal</i> , 2017, 38, ehw203.  | 2.2 | 57        |
| 168 | The hope and the hazards of using compliance data in randomized controlled trials. , 1998, 17, 303-317.   |     | 56        |
| 169 | Design of Major Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2757-2766.  | 2.8 | 56        |
| 170 | Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 629-637. | 1.7 | 56        |
| 171 | Predicting Subclinical Atherosclerosis in Low-Risk Individuals. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2463-2473.   | 2.8 | 55        |
| 172 | Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 375-387.  | 2.9 | 55        |
| 173 | Yoga-Based Cardiac Rehabilitation After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1551-1561.  | 2.8 | 55        |
| 174 | Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1321-1332.  | 2.8 | 55        |
| 175 | 10-Year Mortality Outcome of a Routine Invasive Strategy Versus a Selective Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2015, 66, 511-520.  | 2.8 | 54        |
| 176 | Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1349-1357.  | 2.9 | 54        |
| 177 | Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. <i>European Heart Journal</i> , 2021, 42, 4624-4634.  | 2.2 | 54        |
| 178 | International differences in treatment effect: do they really exist and why? <i>European Heart Journal</i> , 2013, 34, 1846-1852.   | 2.2 | 53        |
| 179 | Do Current Clinical Trials Meet Society's Needs?. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1615-1628.   | 2.8 | 53        |
| 180 | Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. <i>European Heart Journal</i> , 2015, 36, 1106-1114.                                   | 2.2 | 53        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 181 | Challenging Issues in Clinical Trial Design. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2886-2898.  | 2.8 | 52        |
| 182 | Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 504-510.   | 7.1 | 52        |
| 183 | Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation. <i>JAMA Cardiology</i> , 2021, 6, 410.  | 6.1 | 52        |
| 184 | Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1337-1348.  | 2.8 | 52        |
| 185 | Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: Protocol for a randomized, placebo-controlled trial. <i>International Journal of Stroke</i> , 2016, 11, 683-694.   | 5.9 | 50        |
| 186 | Regression to the Mean in SYMPPLICITY-HTN-3. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2016-2025.  | 2.8 | 50        |
| 187 | Linearly divergent treatment effects in clinical trials with repeated measures: efficient analysis using summary statistics. <i>Statistics in Medicine</i> , 1997, 16, 2855-2872.   | 1.6 | 49        |
| 188 | The simplest statistical test: how to check for a difference between treatments. <i>BMJ: British Medical Journal</i> , 2006, 332, 1256.   | 2.3 | 47        |
| 189 | Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1188-1196.                         | 2.3 | 46        |
| 190 | Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2102-2112.  | 2.8 | 45        |
| 191 | Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. <i>EuroIntervention</i> , 2021, 17, e898-e909.   | 3.2 | 45        |
| 192 | A win ratio approach to comparing continuous non-normal outcomes in clinical trials. <i>Pharmaceutical Statistics</i> , 2016, 15, 238-245.  | 1.3 | 44        |
| 193 | Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. <i>European Heart Journal</i> , 2017, 38, 1048-1055. | 2.2 | 44        |
| 194 | Use of Ordinal Outcomes in Vascular Prevention Trials. <i>Stroke</i> , 2008, 39, 2817-2823.   | 2.0 | 43        |
| 195 | Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 895-902.                       | 3.9 | 43        |
| 196 | International patterns of dual antiplatelet therapy duration after acute coronary syndromes. <i>Heart</i> , 2017, 103, 132-138.   | 2.9 | 43        |
| 197 | Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 345-351.   | 7.1 | 43        |
| 198 | Analysis of recurrent events with an associated informative dropout time: Application of the joint frailty model. <i>Statistics in Medicine</i> , 2016, 35, 2195-2205.  | 1.6 | 41        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 199 | Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 3-12.  | 1.0  | 41        |
| 200 | Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2017-2025.  | 2.9  | 41        |
| 201 | Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 949-959.   | 11.4 | 41        |
| 202 | Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials. <i>American Heart Journal</i> , 2016, 171, 40-47. | 2.7  | 40        |
| 203 | External Validation of the MEESSE Acute Heart Failure Risk Score. <i>Annals of Internal Medicine</i> , 2019, 170, 248.  | 3.9  | 40        |
| 204 | Randomized Trials, Statistics, and Clinical Inference. <i>Journal of the American College of Cardiology</i> , 2010, 55, 428-431.  | 2.8  | 39        |
| 205 | Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. <i>European Heart Journal</i> , 2022, 43, 3435-3446.   | 2.2  | 39        |
| 206 | Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: retrospective data for 10 256 individuals from the United Kingdom and Germany. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 389-399.   | 4.4  | 38        |
| 207 | Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 4442-4451.   | 2.2  | 38        |
| 208 | Current challenges for clinical trials of cardiovascular medical devices. <i>International Journal of Cardiology</i> , 2014, 175, 30-37.  | 1.7  | 37        |
| 209 | Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1461-1469.   | 2.9  | 37        |
| 210 | In-Hospital Coronary Revascularization Rates and Post-Discharge Mortality Risk in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1454-1461.   | 2.8  | 37        |
| 211 | Predictors of all-cause mortality and ischemic events within and beyond 1 year after an acute coronary syndrome: Results from the EPICOR registry. <i>Clinical Cardiology</i> , 2019, 42, 111-119.  | 1.8  | 37        |
| 212 | Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. <i>BMC Medicine</i> , 2018, 16, 116.  | 5.5  | 36        |
| 213 | Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2474-2485.  | 4.4  | 36        |
| 214 | Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1129-1137.  | 2.8  | 36        |
| 215 | STATISTICAL REPORTING OF CLINICAL TRIALS WITH INDIVIDUAL CHANGES FROM ALLOCATED TREATMENT. , 1996, 15, 249-262.   |      | 35        |
| 216 | Analysis of How Emergency Physicians'™ Decisions to Hospitalize or Discharge Patients With Acute Heart Failure Match the Clinical Risk Categories of the MEESSE-AHF Scale. <i>Annals of Emergency Medicine</i> , 2019, 74, 204-215.   | 0.6  | 35        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 217 | Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1468-1483.  | 2.8  | 35        |
| 218 | Regional variations in hospital management and post-discharge mortality in patients with non-ST-segment elevation acute coronary syndrome. <i>Clinical Research in Cardiology</i> , 2018, 107, 836-844.   | 3.3  | 34        |
| 219 | Use of the Win Ratio in Cardiovascular Trials. <i>JACC: Heart Failure</i> , 2020, 8, 441-450.   | 4.1  | 34        |
| 220 | Prediction of short-term survival with an application in primary biliary cirrhosis. <i>Statistics in Medicine</i> , 1992, 11, 1731-1745.  | 1.6  | 33        |
| 221 | MRAs in Elderly HF Patients. <i>JACC: Heart Failure</i> , 2019, 7, 1012-1021.   | 4.1  | 33        |
| 222 | Predicting two-year mortality from discharge after acute coronary syndrome: An internationally-based risk score. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 727-737.   | 1.0  | 33        |
| 223 | Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 4455-4464.   | 2.2  | 33        |
| 224 | The data monitoring experience in the MOXCON trial. <i>European Heart Journal</i> , 2004, 25, 1974-1978.  | 2.2  | 32        |
| 225 | The rise, fall, and possible resurrection of renal denervation. <i>Nature Reviews Cardiology</i> , 2016, 13, 238-244.   | 13.7 | 32        |
| 226 | White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .   | 3.9  | 32        |
| 227 | Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from the EMPEROR-Reduced. <i>European Journal of Heart Failure</i> , 2022, 24, 708-715.   | 7.1  | 32        |
| 228 | Figures in clinical trial reports: current practice & scope for improvement. <i>Trials</i> , 2007, 8, 36.   | 1.6  | 31        |
| 229 | Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 121-129.                        | 1.0  | 31        |
| 230 | Learning from recent trials and shaping the future of acute heart failure trials. <i>American Heart Journal</i> , 2013, 166, 629-635.   | 2.7  | 30        |
| 231 | Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. <i>European Heart Journal</i> , 2015, 36, 2310-2317.  | 2.2  | 30        |
| 232 | Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 200-205.  | 3.0  | 30        |
| 233 | Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1529-1538. | 7.1  | 30        |
| 234 | Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. <i>European Heart Journal</i> , 2022, 43, 2984-2993.   | 2.2  | 30        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 235 | Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 35-45.   | 11.4 | 29        |
| 236 | Randomized clinical trials with added rescue medication: some approaches to their analysis and interpretation. <i>Statistics in Medicine</i> , 2001, 20, 2995-3008.   | 1.6  | 28        |
| 237 | The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2005, 149, 939-943.  | 2.7  | 28        |
| 238 | More on Subgroup Analyses in Clinical Trials. <i>New England Journal of Medicine</i> , 2008, 358, 2076-2077.  | 27.0 | 28        |
| 239 | Challenges in the Design and Interpretation of Noninferiority Trials. <i>Journal of the American College of Cardiology</i> , 2017, 70, 894-903.   | 2.8  | 28        |
| 240 | Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008603.   | 3.9  | 28        |
| 241 | Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. <i>Clinical Research in Cardiology</i> , 2020, 109, 289-302.   | 3.3  | 28        |
| 242 | Primary and Secondary Outcome Reporting in Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2021, 78, 827-839.   | 2.8  | 28        |
| 243 | Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term risk, clinical management and healthcare Resource utilization of stable coronary artery disease (TIGRIS) observational study. <i>International Journal of Cardiology</i> , 2017, 236, 54-60.   | 1.7  | 27        |
| 244 | Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 444-456.   | 2.9  | 27        |
| 245 | Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1028-1038.  | 2.8  | 27        |
| 246 | Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2021, 6, 1032.  | 6.1  | 27        |
| 247 | Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. <i>European Heart Journal</i> , 2008, 30, 338-345.  | 2.2  | 26        |
| 248 | Rationale, Design, and Baseline Characteristics of the EPICOR Asia Study (Long-term follow-up of antithrombotic management patterns in Acute T1/T2/T3/T4/T5/T6/T7/T8/T9/T10/T11/T12/T13/T14/T15/T16/T17/T18/T19/T20/T21/T22/T23/T24/T25/T26/T27/T28/T29/T30/T31/T32/T33/T34/T35/T36/T37/T38/T39/T40/T41/T42/T43/T44/T45/T46/T47/T48/T49/T50/T51/T52/T53/T54/T55/T56/T57/T58/T59/T60/T61/T62/T63/T64/T65/T66/T67/T68/T69/T70/T71/T72/T73/T74/T75/T76/T77/T78/T79/T80/T81/T82/T83/T84/T85/T86/T87/T88/T89/T90/T91/T92/T93/T94/T95/T96/T97/T98/T99/T100) | 1.8  | 26        |
| 249 | A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data. <i>Drug Safety</i> , 2020, 43, 623-633.  | 3.2  | 26        |
| 250 | Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2022, 24, 245-248.  | 7.1  | 26        |
| 251 | Eliciting and using expert opinions about influence of patient characteristics on treatment effects: a Bayesian analysis of the CHARM trials. <i>Statistics in Medicine</i> , 2005, 24, 3805-3821.  | 1.6  | 25        |
| 252 | Data monitoring in randomized controlled trials: surveys of recent practice and policies. <i>Clinical Trials</i> , 2005, 2, 22-33.  | 1.6  | 25        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 253 | Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. <i>American Heart Journal</i> , 2017, 188, 73-81.  | 2.7 | 25        |
| 254 | Infections Up to 76 Days After Stroke Increase Disability and Death. <i>Translational Stroke Research</i> , 2017, 8, 541-548.  | 4.2 | 25        |
| 255 | Safety and Efficacy of Intensive vs. Guideline Antiplatelet Therapy in High-Risk Patients with Recent Ischemic Stroke or Transient Ischemic Attack: Rationale and Design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) Trial (ISRCTN47823388). <i>International Journal of Stroke</i> . 2015, 10, 1159-1165. | 5.9 | 24        |
| 256 | Association Between a Social-Business Eating Pattern and Early Asymptomatic Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2016, 68, 805-814.   | 2.8 | 24        |
| 257 | Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006144.   | 3.9 | 24        |
| 258 | Statistical Appraisal of Recent Clinical Trials in Cardiology. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2740-2755.   | 2.8 | 24        |
| 259 | Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT. <i>European Journal of Heart Failure</i> , 2020, 22, 1615-1624.   | 7.1 | 24        |
| 260 | VALIDATION OF A QUESTIONNAIRE TO MEASURE OVERALL MEDITERRANEAN LIFESTYLE HABITS FOR RESEARCH APPLICATION: THE MEDITERRANEAN LIFESTYLE INDEX (MEDLIFE). <i>Nutricion Hospitalaria</i> , 2015, 32, 1153-63.  | 0.3 | 24        |
| 261 | Heart omics™ in AGEing (HOMAGE): design, research objectives and characteristics of the common database. <i>Journal of Biomedical Research</i> , 2014, 28, 349.  | 1.6 | 24        |
| 262 | Patients with acute heart failure discharged from the emergency department and classified as low risk by the MEESI score (multiple risk estimate based on the Spanish emergency department scale): prevalence of adverse events and predictability. <i>Emergencias</i> , 2019, 31, 5-14.   | 0.6 | 24        |
| 263 | A major trial needs three statisticians: why, how and who?. <i>Statistics in Medicine</i> , 2004, 23, 1535-1539.   | 1.6 | 23        |
| 264 | When to Stop a Clinical Trial Early for Benefit: Lessons Learned and Future Approaches. <i>Circulation: Heart Failure</i> , 2012, 5, 294-302.  | 3.9 | 23        |
| 265 | Large streamlined trials in cardiovascular disease. <i>European Heart Journal</i> , 2014, 35, 544-548.   | 2.2 | 23        |
| 266 | Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. <i>Journal of the American Heart Association</i> , 2021, 10, e021965.   | 3.7 | 23        |
| 267 | Incidence and Impact of Totally Occluded Culprit Coronary Arteries in Patients Presenting With Non-ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2015, 115, 428-433.   | 1.6 | 22        |
| 268 | Statistical Analysis Plan for the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke™ (TARDIS) Trial. <i>International Journal of Stroke</i> , 2015, 10, 449-451.   | 5.9 | 22        |
| 269 | Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. <i>Canadian Journal of Cardiology</i> , 2018, 34, 319-329.  | 1.7 | 22        |
| 270 | Critical Appraisal of the 2018 ACC Scientific Sessions Late-Breaking Trials From a Statistician's Perspective. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2957-2969.   | 2.8 | 22        |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 271 | Effect of Barthel Index on the Risk of Thirty-Day Mortality in Patients With Acute Heart Failure Attending the Emergency Department: A Cohort Study of Nine Thousand Ninety-Eight Patients From the Epidemiology of Acute Heart Failure in Emergency Departments Registry. <i>Annals of Emergency Medicine</i> , 2019, 73, 589-598. | 0.6  | 22        |
| 272 | Issues in regulatory guidelines for data monitoring committees. <i>Clinical Trials</i> , 2004, 1, 162-169.  | 1.6  | 21        |
| 273 | Safety of drug-eluting stents: demystifying network meta-analysis. <i>Lancet, The</i> , 2007, 370, 2099-2100.   | 13.7 | 21        |
| 274 | How to interpret figures in reports of clinical trials. <i>BMJ: British Medical Journal</i> , 2008, 336, 1166-1169.   | 2.3  | 21        |
| 275 | Are risk minimization measures for approved drugs in Europe effective? A systematic review. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 443-454.   | 2.4  | 21        |
| 276 | Effectiveness and cost-effectiveness of a Yoga-based Cardiac Rehabilitation (Yoga-CaRe) program following acute myocardial infarction: Study rationale and design of a multi-center randomized controlled trial. <i>International Journal of Cardiology</i> , 2019, 280, 14-18.   | 1.7  | 21        |
| 277 | Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 525-532.   | 4.4  | 21        |
| 278 | Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008226.  | 3.9  | 21        |
| 279 | Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the <sc>EMPEROR</sc> Preserved trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1798-1799.   | 7.1  | 21        |
| 280 | Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the <sc>EMPEROR</sc> Preserved trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1869-1878.   | 7.1  | 21        |
| 281 | Ambulance-delivered transdermal glyceryl trinitrate versus sham for ultra-acute stroke: Rationale, design and protocol for the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2) trial (ISRCTN26986053). <i>International Journal of Stroke</i> , 2019, 14, 191-206.                             | 5.9  | 20        |
| 282 | Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 66-78.   | 4.4  | 20        |
| 283 | Improving public health by improving clinical trial guidelines and their application. <i>European Heart Journal</i> , 2017, 38, 1632-1637.  | 2.2  | 19        |
| 284 | Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1638-1646.   | 1.6  | 19        |
| 285 | Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2020, 22, 1402-1411.  | 7.1  | 19        |
| 286 | Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 2393-2398.   | 7.1  | 19        |
| 287 | Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 291-301.  | 3.0  | 19        |
| 288 | Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. <i>Clinical Cardiology</i> , 2020, 43, 24-32.   | 1.8  | 18        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 289 | Health-related quality of life 1–3 years post-myocardial infarction: its impact on prognosis. <i>Open Heart</i> , 2021, 8, e001499.   | 2.3 | 18        |
| 290 | Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , 2021, 42, 4683-4693.  | 2.2 | 18        |
| 291 | Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 645-654.                               | 2.9 | 17        |
| 292 | New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. <i>European Journal of Heart Failure</i> , 2017, 19, 718-727.  | 7.1 | 17        |
| 293 | Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007133.  | 3.9 | 17        |
| 294 | Synergistic Impact of Systolic Blood Pressure and Perfusion Status on Mortality in Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007347.  | 3.9 | 17        |
| 295 | Tranexamic acid to improve functional status in adults with spontaneous intracerebral haemorrhage: the TICH-2 RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-48.  | 2.8 | 17        |
| 296 | Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. <i>Trials</i> , 2013, 14, 401.   | 1.6 | 16        |
| 297 | Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). <i>European Journal of Heart Failure</i> , 2015, 17, 707-716.   | 7.1 | 16        |
| 298 | The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E112-E119.                         | 1.7 | 16        |
| 299 | Characteristics and outcomes of medically managed patients with non-ST-segment elevation acute coronary syndromes: Insights from the multinational EPICOR Asia study. <i>International Journal of Cardiology</i> , 2017, 243, 15-20.  | 1.7 | 15        |
| 300 | Statistical analysis plan for the Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage™ (TICH-2) trial. <i>Trials</i> , 2017, 18, 607.  | 1.6 | 15        |
| 301 | Estimating the Lifetime Benefits of Treatments for Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 984-995.  | 4.1 | 15        |
| 302 | The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 662-674. | 4.4 | 15        |
| 303 | Contemporary inter-hospital transfer patterns for the management of acute coronary syndrome patients: Findings from the EPICOR study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 254-262.  | 1.0 | 14        |
| 304 | The science of risk models. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 7-13.  | 1.8 | 13        |
| 305 | Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E217-E225.  | 1.7 | 13        |
| 306 | Antithrombotic management and long-term outcomes following percutaneous coronary intervention for acute coronary syndrome in Asia. <i>International Journal of Cardiology</i> , 2020, 310, 16-22.   | 1.7 | 13        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 307 | Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. JACC: Cardiovascular Interventions, 2021, 14, 1434-1446.  | 2.9 | 13        |
| 308 | Life as an academic medical statistician and how to survive it. Statistics in Medicine, 1995, 14, 209-222.   | 1.6 | 12        |
| 309 | THE ROLE OF EXTERNAL EVIDENCE IN DATA MONITORING OF A CLINICAL TRIAL. , 1996, 15, 1285-1293.   |     | 12        |
| 310 | Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the <sc>EMPHASIS&lt;/sc> study. European Journal of Heart Failure, 2016, 18, 1175-1181.                          | 7.1 | 12        |
| 311 | Rationale and design of the long-term risk, clinical management, and healthcare Resource utilization of stable coronary artery disease in post-myocardial infarction patients (TIGRIS) study. Clinical Cardiology, 2017, 40, 1197-1204.  | 1.8 | 12        |
| 312 | Development of a Yoga-Based Cardiac Rehabilitation (Yoga-CaRe) Programme for Secondary Prevention of Myocardial Infarction. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-7.  | 1.2 | 12        |
| 313 | Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age. JACC: Cardiovascular Interventions, 2019, 12, 983-992.   | 2.9 | 12        |
| 314 | Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. International Journal of Cardiology, 2019, 275, 31-35.  | 1.7 | 12        |
| 315 | Prioritised endpoints for device-based hypertension trials: the win ratio methodology. EuroIntervention, 2021, 16, e1496-e1502.  | 3.2 | 12        |
| 316 | Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients. Current Medical Research and Opinion, 2015, 31, 1903-1909.   | 1.9 | 11        |
| 317 | Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. International Journal of Cardiology, 2017, 243, 132-139. | 1.7 | 11        |
| 318 | Predictors of high-cost hospitalization in the treatment of acute coronary syndrome in Asia: findings from EPICOR Asia. BMC Cardiovascular Disorders, 2018, 18, 139.   | 1.7 | 11        |
| 319 | Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the <sc>DISCOVER</sc> study. Diabetes, Obesity and Metabolism, 2021, 23, 39-48.   | 4.4 | 11        |
| 320 | Individualizing treatment choices using quantitative methods. American Heart Journal, 2014, 168, 607-610.  | 2.7 | 10        |
| 321 | Bleeding Events Before Coronary Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2016, 68, 2608-2618.   | 2.8 | 10        |
| 322 | Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of) Tj ETQq0 0 0 rgBT /Overlock 10 2017, 120, 904-910.   | 1.6 | 10        |
| 323 | 1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2020, 13, 820-830.  | 2.9 | 10        |
| 324 | Ethical Dilemmas and Malfunctions in Clinical Trials Research. Annals of Internal Medicine, 2012, 156, 746.  | 3.9 | 9         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 325 | Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. <i>European Heart Journal</i> , 2013, 34, 1621-1629.   | 2.2  | 9         |
| 326 | Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2019, 123, 709-716.                        | 1.6  | 9         |
| 327 | Effect of hospital volume on 90-day mortality after radical cystectomy for bladder cancer in Spain. <i>World Journal of Urology</i> , 2020, 38, 1221-1228.   | 2.2  | 9         |
| 328 | Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. <i>International Journal of Cardiology</i> , 2020, 311, 7-14.   | 1.7  | 9         |
| 329 | Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 391-400. | 1.7  | 8         |
| 330 | Statistical analysis plan for the "Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2)". <i>European Stroke Journal</i> , 2018, 3, 193-196.   | 5.5  | 8         |
| 331 | The Usefulness of the MEESI Score for Risk Stratification of Patients With Acute Heart Failure at the Emergency Department. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2019, 72, 198-207.  | 0.6  | 8         |
| 332 | Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-76.   | 2.8  | 8         |
| 333 | Effects of long-term use of cardiovascular drugs. <i>Lancet, The</i> , 2015, 385, 325.   | 13.7 | 7         |
| 334 | The Nature of the P Value. <i>New England Journal of Medicine</i> , 2016, 375, 2205-2206.  | 27.0 | 7         |
| 335 | Individualizing treatment choices in the systolic blood pressure intervention trial. <i>Journal of Hypertension</i> , 2018, 36, 428-435.   | 0.5  | 7         |
| 336 | Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e004945.   | 2.2  | 7         |
| 337 | Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. Translation to Russian. <i>Digital Diagnostics</i> , 2021, 2, 119-169.   | 0.6  | 7         |
| 338 | Evaluation of Antiarrhythmic Drug Efficacy in Patients with an ICD:.. <i>Journal of Cardiovascular Electrophysiology</i> , 1999, 10, 1534-1549.  | 1.7  | 6         |
| 339 | Oseltamivir for influenza " Authors' reply. <i>Lancet, The</i> , 2015, 386, 1135-1136.   | 13.7 | 6         |
| 340 | Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. <i>American Journal of Cardiology</i> , 2016, 118, 1661-1668.                                       | 1.6  | 6         |
| 341 | Central adjudication of serious adverse events did not affect trial's safety results: Data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. <i>PLoS ONE</i> , 2018, 13, e0208142.   | 2.5  | 6         |
| 342 | Two-year outcomes post-discharge in Asian patients with acute coronary syndrome: Findings from the EPICOR Asia study. <i>International Journal of Cardiology</i> , 2020, 315, 1-8.   | 1.7  | 6         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 343 | Long-term antithrombotic management patterns in Asian patients with acute coronary syndrome: 2-year observations from the EPICOR Asia study. <i>Clinical Cardiology</i> , 2020, 43, 999-1008.  | 1.8 | 6         |
| 344 | Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .                               | 3.0 | 6         |
| 345 | Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 282-293.   | 2.9 | 6         |
| 346 | Optimal Sequential Screening Guidelines for Quantitative Risk Factors Measured with Error. <i>Journal of the American Statistical Association</i> , 1995, 90, 19-26.   | 3.1 | 5         |
| 347 | Baseline characteristics, analysis plan and report on feasibility for the Prevention Of Decline in Cognition After Stroke Trial (PODCAST). <i>Trials</i> , 2015, 16, 509.  | 1.6 | 5         |
| 348 | Baseline characteristics of the 3096 patients recruited into the "Triple Antiplatelets for Reducing Dependency after Ischemic Stroke" trial. <i>International Journal of Stroke</i> , 2017, 12, 524-538.   | 5.9 | 5         |
| 349 | Central masked adjudication of stroke diagnosis at trial entry offered no advantage over diagnosis by local clinicians: Secondary analysis and simulation. <i>Contemporary Clinical Trials Communications</i> , 2018, 12, 176-181.   | 1.1 | 5         |
| 350 | Raised blood pressure and risk of dementia. <i>European Heart Journal</i> , 2019, 40, 785-786.   | 2.2 | 5         |
| 351 | Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 42-51.   | 2.1 | 5         |
| 352 | Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate. <i>Clinical Research in Cardiology</i> , 2019, 108, 806-814.   | 3.3 | 5         |
| 353 | Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention"Results from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 885-892.             | 1.7 | 5         |
| 354 | The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 453-459. | 3.0 | 5         |
| 355 | Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. <i>Clinical Research in Cardiology</i> , 2020, 109, 725-734.  | 3.3 | 5         |
| 356 | Sex differences in mortality after an acute coronary syndrome increase with lower country wealth and higher income inequality. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2022, 75, 392-400.   | 0.6 | 5         |
| 357 | Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 707-716.  | 3.0 | 5         |
| 358 | Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. <i>EuroIntervention</i> , 2022, 17, 1330-1339.   | 3.2 | 5         |
| 359 | Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction. <i>Open Heart</i> , 2021, 8, e001726.  | 2.3 | 5         |
| 360 | Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis of the EPICOR registry. <i>Open Heart</i> , 2016, 3, e000347.  | 2.3 | 4         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 361 | Association Between Clinical Pathways Leading to Medical Management and Prognosis in Patients With NSTEMI. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 817-824.   | 0.6  | 4         |
| 362 | Ever-Pregnant Female Blood Donors and Mortality Risk in Male Recipients. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1048.   | 7.4  | 4         |
| 363 | Predicting 30-Day Mortality for Patients With Acute Heart Failure in the Emergency Department. <i>Annals of Internal Medicine</i> , 2018, 168, 899.   | 3.9  | 4         |
| 364 | Prolonged dual antiplatelet therapy in patients with non-ST-segment elevation myocardial infarction: 2-year findings from EPICOR Asia. <i>Clinical Cardiology</i> , 2020, 43, 346-354.  | 1.8  | 4         |
| 365 | Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials. <i>BMC Medical Research Methodology</i> , 2021, 21, 218.   | 3.1  | 4         |
| 366 | Authors' response to "Comment on adaptive increase in sample size when interim results are promising". <i>Statistics in Medicine</i> , 2011, 30, 3302-3303.   | 1.6  | 3         |
| 367 | Association Between Anthropometry and High Blood Pressure in a Representative Sample of Preschoolers in Madrid. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 477-484.  | 0.6  | 3         |
| 368 | Associations between change in blood pressure and functional outcome, early events and death. <i>Journal of Hypertension</i> , 2019, 37, 2104-2109.   | 0.5  | 3         |
| 369 | Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme. <i>BMJ Open</i> , 2020, 10, e034613.  | 1.9  | 3         |
| 370 | Diabetes association with self-reported health, resource utilization, and prognosis post-myocardial infarction. <i>Clinical Cardiology</i> , 2020, 43, 1352-1361.   | 1.8  | 3         |
| 371 | Blood pressure reduction and anti-hypertensive treatment choice: A post-hoc analysis of the SPRINT trial. <i>Clinical Cardiology</i> , 2021, 44, 665-674.   | 1.8  | 3         |
| 372 | Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008075.  | 3.9  | 3         |
| 373 | A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions. <i>Contemporary Clinical Trials Communications</i> , 2021, 23, 100818.   | 1.1  | 3         |
| 374 | Response to Letter Regarding Article, "Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications: Assessment From the Acute Catheterization and Urgent Intervention Triage Strategy Trial". <i>Circulation</i> , 2010, 122, . | 1.6  | 2         |
| 375 | Does midlife obesity really lower dementia risk? "Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 501-502.  | 11.4 | 2         |
| 376 | RAPID INTERVENTION WITH GLYCERYL TRINITRATE IN HYPERTENSIVE STROKE TRIAL-2 (RIGHT-2): SAFETY AND EFFICACY OF TRANSDERMAL GLYCERYL TRINITRATE, A NITRIC OXIDE DONOR. <i>Emergency Medicine Journal</i> , 2016, 33, e13.2-e14.  | 1.0  | 2         |
| 377 | Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1704-1711.  | 3.4  | 2         |
| 378 | Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 53-60.  | 1.7  | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 379 | Relationship between nitrate headache and outcome in patients with acute stroke: results from the efficacy of nitric oxide in stroke (ENOS) trial. <i>Stroke and Vascular Neurology</i> , 2021, 6, 180-186.                          | 3.3 | 2         |
| 380 | The Clinical outcomes, healthcare resource utilization, and related costs (COHERENT) model. Application in heart failure patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, , .                                   | 0.6 | 2         |
| 381 | Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. <i>Journal of Cardiology</i> , 2021, , .  | 1.9 | 2         |
| 382 | Covariate Adjustment in Cardiovascular Randomized Controlled Trials. <i>JACC: Heart Failure</i> , 2022, 10, 297-305.   | 4.1 | 2         |
| 383 | Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2022, 21, 173-208.   | 0.4 | 2         |
| 384 | RE: "QUALITY OF REPORTING OF OBSERVATIONAL LONGITUDINAL RESEARCH". <i>American Journal of Epidemiology</i> , 2005, 162, 1032-1033.   | 3.4 | 1         |
| 385 | The Use of Figures in Epidemiological Publications: A Survey of Current Practice and Consequent Recommendations. , 2012, , 71-83.  |     | 1         |
| 386 | A win ratio approach to comparing ordinal or non-normal outcomes in clinical trials. <i>Trials</i> , 2013, 14, .   | 1.6 | 1         |
| 387 | PREDICTORS OF ISCHEMIC EVENTS WITHIN AND AFTER 1 YEAR AFTER AN ACUTE CORONARY SYNDROME: RESULTS FROM THE EPICOR REGISTRY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 230.                                      | 2.8 | 1         |
| 388 | Long-term antiplatelet therapy in medically managed non-ST-segment elevation acute coronary syndromes: The EPICOR Asia study. <i>International Journal of Cardiology</i> , 2021, 327, 19-24.   | 1.7 | 1         |
| 389 | Number of Antithrombotic Drugs Used Early and In-hospital Outcomes in Acute Coronary Syndromes. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 790-798.   | 2.4 | 1         |
| 390 | Long-Term Antithrombotic Therapy and Clinical Outcomes in Patients with Acute Coronary Syndrome and Renal Impairment: Insights from EPICOR and EPICOR Asia. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 471-482.     | 2.2 | 1         |
| 391 | Lowering systolic blood pressure to 120%mmHg or The Lancet's true grit. <i>European Heart Journal</i> , 2021, 42, 2052-2059.   | 2.2 | 1         |
| 392 | Implications of Biomarker Discordance After Coronary Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2978-2980.   | 2.8 | 1         |
| 393 | STATISTICAL REPORTING OF CLINICAL TRIALS WITH INDIVIDUAL CHANGES FROM ALLOCATED TREATMENT. <i>Statistics in Medicine</i> , 1996, 15, 249-262.  | 1.6 | 1         |
| 394 | The hope and the hazards of using compliance data in randomized controlled trials. <i>Statistics in Medicine</i> , 1998, 17, 303-317.  | 1.6 | 1         |
| 395 | Accounting For Non-Independent Observations In 2x2 Tables, With Application To Correcting For Family Clustering In Exposure-Risk Relationship Studies. <i>Journal of Modern Applied Statistical Methods</i> , 2002, 1, 379-386.      | 0.2 | 1         |
| 396 | Effect of continuing versus stopping pre-stroke antihypertensive agents within 12h on outcome after stroke: A subgroup analysis of the efficacy of nitric oxide in stroke (ENOS) trial. <i>EClinicalMedicine</i> , 2022, 44, 101274. | 7.1 | 1         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 397 | Statistical Essentials in the Design and Analysis of Clinical Trials. , 2016, , 296-300.  |      | 0         |
| 398 | Oseltamivir for influenza – Authors' reply. Lancet, The, 2016, 387, 125.  | 13.7 | 0         |
| 399 | Percutaneous coronary intervention for stable angina in ORBITA. Lancet, The, 2018, 392, 26-27.  | 13.7 | 0         |
| 400 | Response by Claggett et al to Letter Regarding Article, –Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials– Circulation, 2019, 139, 422-423.                        | 1.6  | 0         |
| 401 | Statistical Essentials in the Design and Analysis of Clinical Trials. , 0, , 491-501.   |      | 0         |
| 402 | Abstract MP38: The Program SI! Intervention for Enhancing a Healthy Lifestyle among Children aged 3 to 5: A Cluster Randomized Trial. Circulation, 2014, 129, .   | 1.6  | 0         |
| 403 | Long-Term Outcome of Acute Coronary Syndromes in Patients on Chronic Oral Anticoagulants: Data from the EPICOR Study. Current Vascular Pharmacology, 2019, 18, 92-99.   | 1.7  | 0         |
| 404 | 291 Ticagrelor monotherapy after percutaneous coronary intervention in high-risk patients with prior myocardial infarction: a prespecified twilight substudy. European Heart Journal Supplements, 2021, 23, . | 0.1  | 0         |